TAS-102 Ineffective for Treatment of Small Cell Lung Cancer

Share this content:
TAS-102 showed no activity for the second-line treatment of small cell lung cancer.
TAS-102 showed no activity for the second-line treatment of small cell lung cancer.

TAS-102 improved survival, when contrasted with placebo, for patients with refractory colorectal cancer, though the drug showed no activity for the second-line treatment of patients with small cell lung cancer, according to a study published in the journal Lung Cancer.1

TAS-102 is an orally administered combination of a thymidine-based nucleic acid analogue, trifluridine, and a thymidine phosphorylase inhibitor, tipiracil hydrochloride. TAS-102 has exhibited greater activity than cisplatin in small cell lung cancer xenograft mouse models; researchers therefore evaluated activity and tolerability of the combination drug in this multicenter, open-label, phase 2 study.

Investigators enrolled 18 patients with small cell lung cancer who were refractory or sensitive to frontline platinum-based chemotherapy and who required second-line treatment. Participants were randomly assigned to receive TAS-102 35 mg/m2 orally twice daily or chemotherapy with either topotecan or amrubicin.

Of the 9 patients who received TAS-102, 8 discontinued treatment due to disease progression and 1 patient died as a result of clinical progression during the safety follow-up. In the control arm, 6 patients discontinued treatment for progressive disease and 1 due to an adverse event.

RELATED: Carboplatin, Nab-Paclitaxel Demonstrates Efficacy in Small Cell Lung Cancer

The study was terminated early as it was unlikely that TAS-102 would be superior to chemotherapy. Median progression-free survival was 1.4 months with TAS-102, in contrast with 2.7 months with chemotherapy (hazard ratio, 3.76; 80% CI, 1.68-8.40).


  1. Scagliotti G, Nishio M, Satouchi M, et al. A phase 2 randomized study of TAS-102 versus topotecan or amrubicin in patients requiring second-line chemotherapy for small cell lung cancer refractory or sensitive to frontline platinum-based chemotherapy. Lung Cancer. 2016 Jun 27. doi: 10.1016/j.lungcan.2016.06.023 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs